Archive for ‘Radiology’

Page 1 of 712345...Last »

Diagnostic Imaging Device Market on Track to US$ 35,793.4 Million by 2020

Diagnostic Imaging Device Market on Track to US$ 35,793.4 Million by 2020

Infusion-pumps

 

The global diagnostic imaging devices market is growing at a moderate rate owing to increasing prevalence of chronic diseases and injuries, and growing aging population. Moreover, factors such as rising initiatives undertaken by government associations to boost awareness of the effects and complications of tuberculosis, cardiovascular diseases, and cancer, and technological advancement and widening application of diagnostic imaging devices are driving the global diagnostic imaging devices market. In addition, increasing funding from government bodies is also promoting the use of diagnostic imaging devices in the regions. However, factors such as strict regulatory requirements and heightened risk of cancer owing to exposure to radiation are inhibiting the market growth.

The global diagnostic imaging devices market was valued at USD 26,477.1 million in 2014 and is expected to grow at a CAGR of 5.2% from 2014 to 2020, to reach an estimated value of USD 35,793.4 million in 2020.

In Europe, the diagnostic imaging devices market is driven by rising diagnostic requirements due to increasing prevalence of chronic diseases and injuries, and aging population. For instance, according to a paper published on Cancer Incidence and Mortality Pattern in Europe, by International Agency for Research on Cancer in France, approximately, 3.45 million new cases of cancer were diagnosed in Europe in 2012.

In North America, growing aging population, increasing health awareness, rising chronic diseases and injuries, large number of ongoing research activities and faster adoption of technologically advanced imaging systems are driving the use of diagnostic imaging devices in the market.

Request to view Table of Content @ http://www.persistencemarketresearch.com/market-research/diagnostic-imaging-devices-market/toc

However, in Asia-Pacific the growth for diagnostic imaging devices is much higher than developed countries due to growing awareness about benefits of early diagnosis of disease among individuals, large population base, upgradation of health care systems and increasing prevalence of chronic diseases.

To Purchase Single User License @ http://www.persistencemarketresearch.com/checkout/2822

Siemens Healthcare, Hitachi, Ltd., Carestream, Health, Inc., Samsung Electronics Co., Ltd., Toshiba Corporation, Koninklijke Philips N.V., and General Electric Company are some of the major players in diagnostic imaging devices market.

About Us

Persistence Market Research (PMR) is a full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.

PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s engagement models are highly flexible without compromising on its deep-seated research values.

Contact

Persistence Market Research

305 Broadway

7th Floor, New York City,

NY 10007, United States

USA – Canada Toll Free: +1 800-961-0353

Email: sales@persistencemarketresearch.com

media@persistencemarketresearch.com

Web: http://www.persistencemarketresearch.com

Full story

ProNova SC360, a New Proton Therapy System Cleared in U.S.

ProNova SC360, a New Proton Therapy System Cleared in U.S.

sc360

 

ProNova Solutions, a division of Provision Healthcare based in Tennessee, won FDA clearance for its ProNova SC360 proton therapy system. It took the firm only four years to develop the system and get it cleared, but Tennessee is famous for its high energy physics expertise, going back to the Manhattan Project. The first SC360 installation already happened at the Provision CARES Proton Therapy Center in Knoxville, TN and the first patients are expected to be treated in the coming year.

The ProNova SC360 allows patients to be treated at any angle without having to move them, instead directing the beam to come from any direction chosen by the clinical team. This should allow for faster treatment times as patients don’t have to be repositioned to deliver energy from different angles.

It features pencil beam scanning and a built-in cone-beam CT for imaging the patients. Positron emission tomography (PET) capabilities are optionally available as well.

The system is designed to be able to power two treatment rooms at the same time, but single and three-room options can be made available as well.

Product page: ProNova SC360…

Via: Provision Healthcare…

Full story

DiCoMo’s Novel X-Ray Detector Technology to Allow for Low-Dose, High-Resolution Imaging and Diagnosis

DiCoMo’s Novel X-Ray Detector Technology to Allow for Low-Dose, High-Resolution Imaging and Diagnosis

image1

 

The DiCoMo (“Direct conversion hybrid-organic X-ray detectors on metal oxide backplane”) Project promises to remove the need for diagnosticians to reconcile the value of high-resolution scanning with the safety concerns associated with exposure to high doses of ionizing radiation through the development of a novel X-ray detector. Their flat panel digital X-ray detector technology draws upon advancements in photonics to improve the specificity and sensitivity of low-radiation scanning systems, thereby enabling low-cost, effective diagnosis and preventive care without endangering patients or radiology staff.

Essential radiographic imaging techniques such as X-ray and X-ray computed tomography (CT) scanning allow for visualization of internal structures by penetrating tissues with high-energy particles that produce harmful ionizing radiation. With traditional radiography systems, higher doses of radiation are required to image at high-resolution. However, additional radiation exposure creates extra risks of health consequences. As such, medical professionals are currently forced to mediate the risk and reward trade off on an application-specific basis, selecting a scanning configuration and detector type that is appropriate for visualizing a given structure or phenomenon.

Some common X-ray scanning techniques require high-resolution imaging to be of value, such as mammograms taken to evaluate or screen breast tissue for irregularities. This type of scan traditionally relies on detectors utilizing direct converters. Direct converters translate absorbed X-rays into electrical signals directly, requiring a heavy dose of X-rays and associated radiation in order to maximize spatial resolution. For other applications, especially those seeking to examine bones or other large structures through radiography or fluoroscopy, low-radiation, lower-resolution imaging is often suitable. Such scans employ detectors with indirect converters. In indirect conversion, scintillators produce light upon absorbing X-rays and the electrical signals are ultimately recorded by a photodetector. However, the scintillators create light in all directions upon X-ray irradiation, causing neighboring photodetector array pixels to register a signal, which, in aggregate, lowers the imaging resolution.

detector-dicomoThe DiCoMo Project, a consortium of European partner organizations and institutions coordinated in Germany by Siemens Healthineers, is working towards the development of an alternative, hybrid detector technology. Their detector is said to rely on “quasi-direct” conversion that allows for low-dose, high-resolution imaging. In the DiCoMo detector, the scintillator is embedded into the photodetector. This positioning limits light absorption and signal detection to the exact pixel that each X-ray photon irradiates. Additionally, active pixel sensors amplify the detected signals within each pixel via metal-oxide thin-film transistors, creating a stronger signal. Finally, a custom readout chip helps to more than double traditional detection frame rates, from approximately 60 frames per second (fps) to 130 fps. Taken together, the advanced detector technology thereby enables an unprecedented combination of high-resolution and low-radiation X-ray imaging, and is even capable of capturing fast-moving features.

In 2015, DiCoMo received significant research and innovation funding from the Photonics Public Private Partnership and the European Commission’s Horizon 2020 program. The consortium aims to leverage this funding and its existing progress to complete development of the new X-ray detectors within five years.

For additional Medgadget coverage of Photonics21 and Horizon 2020 projects, refer to this week’s story regarding how the COBIOPHAD device promises quicker, more efficient drug allergy diagnosis.

Press Release: High resolution detectors to create safer X-ray diagnosis…

More Information: DiCoMo…

Full story

MIT Scientists Unveil Radiation-free MRI Brain Imaging Tracer

MIT Scientists Unveil Radiation-free MRI Brain Imaging Tracer

Fig2_injections_v9b

 

Existing methods of spotting the presence of specific molecules in the brain requires using chemical or radioactive markers. These can have side effects for patients, at times be difficult to acquire and use, and they’re limited in their spatial and temporal resolutions. Now scientists at MIT have come up with an entirely new method of imaging molecules that uses targeted proteins and MRI to get a quality picture of activity inside the brain.

The proteins were designed to hold onto a peptide called calcitonin gene-related peptide (CGRP). CGRP is involved in migraines and inflammation, dilating blood vessels as it passes through. The protein/peptide packages are designed to open up when in the presence of proteases, the target molecules the researchers were looking for, and release the CGRP. Since the peptide is released wherever the proteases are present, nearby vessels begin to dilate. This change in blood flow can be spotted using MRI, revealing the location of the target protease molecules.

The same technique is now being translated to target neurotransmitters like dopamine and serotonin. This will require engineering new protein structures that hold onto CGRP and break down when a specific neurotransmitter is present.

From the study abstract in Nature Communications:

Variants of the calcitonin gene-related peptide artificially activate vasodilation pathways in rat brain and induce contrast changes that are readily measured by optical and magnetic resonance imaging. CGRP-based agents induce effects at nanomolar concentrations in deep tissue and can be engineered into switchable analyte-dependent forms and genetically encoded reporters suitable for molecular imaging or cell tracking. Such artificially engineered physiological changes, therefore, provide a highly versatile means for sensitive analysis of molecular events in living organisms.

Open access study in Nature Communications: Molecular imaging with engineered physiology…

Via: MIT…

Full story

Medtronic’s Endurant II/IIs Stent Grafts Cleared in Europe for ChEVAR AAA Procedures

Medtronic’s Endurant II/IIs Stent Grafts Cleared in Europe for ChEVAR AAA Procedures

endurant-ii_epgie_hero

 

Medtronic received the EU CE Mark for its Endurant II/IIs stent grafts to be used to treat abdominal aortic aneurysms (AAA) using the ChEVAR technique (chimney technique in endovascular aortic aneurysm repair). ChEVAR can be particularly useful in timely situations to avoid having to produce patient customized branched and fenestrated stent grafts, as well as for use in patients with short aortic necks.

ChEVAR essentially relies on placing traditional stents or stent grafts linking the main artery with the side branches, and positioning the main stent graft within the aorta and pressing against the side branch stents (see picture).

Some details about the study that led to the approval, according to Medtronic:

In the flagship PROTAGORAS study, outcomes were tracked with radiologic follow up over a mean of two years. The study used a standardized procedural approach with the Endurant system and balloon expandable covered stents. The results, which were published in the Journal of Vascular Surgery, demonstrated that standardized use of the Endurant II/IIs stent graft system with ChEVAR in 128 patients is associated with 100 percent technical success, statistically significant aneurysm sac regression (p = .001), 95.7 percent primary patency of the chimney grafts and a low incidence of chimney related reinterventions.

Source: Medtronic…

Full story

ConvertX Nephroureteral Stent System Avoids Extra Procedure

ConvertX Nephroureteral Stent System Avoids Extra Procedure

convertx

 

BrightWater Medical, a company based in Murrieta, California, won FDA clearance to introduce in the U.S. its ConvertX nephroureteral catheter and stent system for use in treating ureteral obstructions in patients that require perc nephrostomy tubes. The system is intended to be used by interventional radiologists and removes a separate minimally invasive procedure that is required with current treatment.

convertx-2Right now, a nephrostomy catheter is first placed to drain urine into a bag. The patient comes back a few days later to have the catheter removed and a stent placed. The ConvertX is designed to have the stent delivered during catheter placement and expanded once drainage is complete. The catheter essentially transforms into a stent in a quick follow up procedure without needing fluoroscopy or sedating the patient. Once finalized, the stent works like other existing ureteral stents.

“Ureteral blockages due to kidney stones, tumors or scarring from previous surgeries must be treated quickly so urine can be voided,” explained Bob Smouse, M.D., founder and CEO of BrightWater Medical and Professor of Radiology & Surgery at the University of Illinois College of Medicine, in a statement. “The ConvertX System saves the patient the risk and discomfort of an additional second interventional procedure and may reduce healthcare costs, free up the hospital’s angio suite for other procedures and save the IR procedural time that can be devoted to care of other patients.”

Product page with video showing delivery and placement: ConvertX Stent…

Via: BrightWater Medical…

Full story

Mindray Introduces L20-5s Ultra-High Frequency Linear Transducer with Enhanced iNeedle Visualization Technology

Mindray Introduces L20-5s Ultra-High Frequency Linear Transducer with Enhanced iNeedle Visualization Technology

transducer

 

Mindray recently announced the launch of the L20-5s ultra-high frequency linear transducer with enhanced iNeedle visualization technology. This transducer technology leverages the firm’s TE7 point-of-care ultrasound system. This recent innovation in ultrasound technology provides exquisite image quality of soft tissues while preserving visualization of needles used in procedures.

This technology is being targeted at anesthesiologists for use in regional nerve blocks and in placement of ultrasound-guided central lines. Mindray is making a push to improve image quality and usability while reducing procedure time for clinicians in high-stress critical applications such operating rooms, interventional suits, and the intensive care unit. It will be interesting to see the adoption of specialized transducer technologies as use of ultrasound expands owing to portability and lack of reliance on ionizing radiation.

ineedle

Via: Mindray…

Full story

ExactVu Micro-Ultrasound System for Prostate Imaging and Biopsy Guidance Cleared in Europe

ExactVu Micro-Ultrasound System for Prostate Imaging and Biopsy Guidance Cleared in Europe

exact-imaging-system

Exact Imaging, a Canadian firm, won the European CE Mark to introduce its ExactVu prostate imaging and biopsy guidance system to the European market. It is a micro-ultrasound system that provides a resolution down to 70 microns, allowing a physician to visualize the prostate in real time and in high detail. The ExactVu relies on a 29 MHz transducer that is placed directly against the prostate to identify suspect lesion that should be sampled in a biopsy and to help guide the biopsy to the target location.

Besides the high resolution probe that’s inserted through the rear, the system comes with two conventional trans-abdominal probes for kidney, bladder, and prostate imaging. And it includes an integrated disposable biopsy device for a complete package that can be quickly introduced into the clinic.

The unit itself has an adjustable control panel and a touchscreen interface with a bunch of presets one can tune.

“There is significant built-up demand for acquiring the ExactVu instrument and this approval will allow us to be able to commercialize our platform in Europe. said Randy AuCoin, Exact Imaging’s President and CEO, in a statement. “With the ExactVu platform, urologists will have a new level of real-time resolution to facilitate actually targeting their prostate biopsies at suspicious regions. The goal is to provide the best tools to help the urologist make the most informed decisions and ultimately, to improve patient outcomes.”

Here’s a talk by Dr. Sangeet Ghaiof the University of Toronto discussing the clinical implications of micro-ultrasound:

Link: Exact Imaging…

Original announcement…

Full story

LimFlow System: A New Option for Treating Critical Limb Ischemia

LimFlow System: A New Option for Treating Critical Limb Ischemia

limflow

 

If peripheral vascular disease (PAD) is not treated, it can progress toward nearly complete blockage of the arteries that supply the lower extremity with blood and result in critical limb ischemia (CLI). People suffering with the condition experience severe pain, can have gangrene, and have a drastically reduced quality of life. A new device from LimFlow, a company based in Paris, France received the European CE mark to introduce a system that can offer a new option for otherwise untreatable patients.

The LimFlow system is used to link the tibial vein and a diseased tibial artery of the leg so that blood can bypass the arterial occlusion and reach the foot. It relies on two catheters that utilize ultrasound to accurately line up next to each other. Once positioned, a guidewire from the arterial side is used to penetrate into the vein and to then place a covered stent that bridges the vessels. The stent is quite long, continuing toward the foot to provide the necessary support for all the new blood flow.

While not a miracle cure, as the patient will now have blood moving down the vein in the wrong direction, it may prevent terrible consequences such as amputation. “Utilizing the existing alternative pathway of the venous vasculature, the LimFlow System is designed to reestablish perfusion for patients that have chronic, non-healing wounds and are in imminent danger of losing a limb,” said Dan Rose, chief executive officer of LimFlow, in a statement. “We can now provide an option for patients that have none today. In early clinical cases, we have seen patients with extensive and severe foot wounds, including gangrene, fully heal following treatment with the LimFlow therapy, becoming mobile and active again.”

Here’s an animation demonstrating the LimFlow procedure:

Product info page: LimFlow Stent Graft System…

Via: LimFlow

Full story

Siemens’ New Artis Q and Artis Q.zen Angiography Systems

Siemens’ New Artis Q and Artis Q.zen Angiography Systems

Siemens’ New Artis Q and Artis Q.zen Angiography Systems

Siemens Healthcare has developed a revolutionary new X-ray tube and detector technology for its Artis Q and Artis Q.zen angiography systems to improve minimally invasive therapy of diseases such as coronary artery disease, stroke and cancer. In both the Artis Q and Artis Q.zen series, the new X-ray tube can help to identify small vessels up to 70 percent better than conventional X-ray tube technology. The Artis Q.zen combines this innovative X-ray source with a new detector technology that supports interventional imaging in ultra-low-dose ranges. This protects patients, doctors and medical staff, especially during longer interventions. With these new developments, presented for the first time at the 98th Congress of the Radiological Society of North America (RSNA), Siemens Healthcare has once again demonstrated its innovative strength and market competitiveness as part of its Agenda 2013 global Sector initiative.

Siemens presents new product lines for angiography: The Artis Q and Artis Q.zen introduce groundbreaking new X-ray tube and detector technology

Two hardware components are crucial for angiographic image quality: the X-ray tube and the detector. The X-rays emitted by the tube pass through the patient and hit the detector, which converts them to image signals.

The second generation of Siemens’ flat emitter technology is key to the advances made in the X-ray tube for the Artis Q and Artis Q.zen product lines. Instead of the coiled filaments used in conventional X-ray tubes, flat emitter technology is used exclusively in the new tube to emit electrons. Flat emitters enable smaller quadratic focal spots that lead to improved visibility of small vessels by up to 70 percent. Both physicians and patients benefit from a high level of detail in imaging-supported interventional therapy. Neurologists can more precisely measure the blood circulation in specific areas of the brain, for example; while stenoses in the heart’s smallest blood vessels can be spotted in coronary angiography.

Examinations using ultra-low dose radiation

The Artis Q.zen series combines the X-ray tube with a detector technology that allows detection at ultra-low radiation levels. Artis Q.zen imaging can use doses as low as half the usual levels normally applied in angiography. This improvement is the result of several innovations, including a fundamental change in detector technology. Until now, almost all detectors have been based on amorphous silicon. The new crystalline silicon structure of the Artis Q.zen detector is more homogenous, allowing for more effective amplification of the signal, greatly reducing the electronic noise even at ultra-low doses.

The Artis Q.zen was developed to support better imaging quality at ultra-low-dose ranges, reducing the radiation exposure of patients, physicians, and medical staff. This is especially important in dose-sensitive application fields such as pediatric cardiology and radiology, or electrophysiology, which is being used on more and more patients as rates of cardiac arrhythmia increase in an aging population.

Innovative applications for interventional imaging

In addition to the hardware innovations are several software applications that improve interventional imaging. In coronary artery disease treatment, the applications allow precise correlation of angiography images with ultrasound images taken by a probe inside the coronary arteries. Stents are imaged in real-time during therapy, with motion stabilization created by simultaneous correction for the heartbeat.

Other new 3D applications can image the smallest structures inside the head. Their high spatial resolution is crucial for imaging intracranial stents or other miniscule structures, such as the cochlea in the inner ear. Moving organs such as the lungs can be imaged in 3D in less than 3 seconds, reducing the number of motion artifacts and the amount of contrast agent required. Through visualization and measurement of blood volumes in the liver or other organs, Siemens’ functional 3D imaging provides a basis for planning therapies such as chemo-embolization of hepatic tumors.

Launched in November 2011 by the Siemens Healthcare Sector, “Agenda 2013″ is a two-year global initiative to further strengthen the Healthcare Sector’s innovative power and competitiveness. Specific measures will be implemented in four fields of action: Innovation, Competitiveness, Regional Footprint, and People Development.

Press photos for the Artis Q and Artis Q.zen will be available at: www.siemens.com/healthcare-pictures/Artis-Q

The Siemens Healthcare Sector is one of the world’s largest suppliers to the healthcare industry and a trendsetter in medical imaging, laboratory diagnostics, medical information technology and hearing aids. Siemens offers its customers products and solutions for the entire range of patient care from a single source – from prevention and early detection to diagnosis, and on to treatment and aftercare. By optimizing clinical workflows for the most common diseases, Siemens also makes healthcare faster, better and more cost-effective. Siemens Healthcare employs some 51,000 employees worldwide and operates around the world. In fiscal year 2012 (to September 30), the Sector posted revenue of 13.6 billion euros and profit of 1.8 billion euros. For further information please visit: http://www.siemens.com/healthcare

The products/features (here mentioned) are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed. Please contact your local Siemens organization for further details.

Siemens has unveiled two new angiography systems at RSNA in Chicago that feature brand new X-ray tubes and detectors that together produce a substantially higher spatial resolution over previous generation systems. brain drainage stent Siemens New Artis Q and Artis Q.zen Angiography SystemsThe new systems allow neuro and cardiac surgeons to visualize small vessels with greater precision during interventional procedures and provide options for radiation dose reduction where the absolute best possible imaging is not necessary.

As an example of what is possible with the new angiography systems, Siemens was showing off an image of an implanted neuro drainage stent that’s about the width of a human hair. Pretty remarkable if you ask us.

More from Siemens:

Instead of the coiled filaments used in conventional X-ray tubes, flat emitter technology is used exclusively in the new tube to emit electrons. Flat emitters enable smaller quadratic focal spots that lead to improved visibility of small vessels by up to 70 percent. In addition to the hardware innovations are several software applications that improve interventional imaging. In coronary artery disease treatment, the applications allow precise correlation of angiography images with ultrasound images taken by a probe inside the coronary arteries.

Artis Q and Artis Q.zen side Siemens New Artis Q and Artis Q.zen Angiography SystemsStents are imaged in real-time during therapy, with motion stabilization created by simultaneous correction for the heartbeat.The Artis Q.zen series combines the X-ray tube with a detector technology that allows detection at ultra-low radiation levels. Artis Q.zen imaging can use doses as low as half the usual levels normally applied in angiography. This improvement is the result of several innovations, including a fundamental change in detector technology. Until now, almost all detectors have been based on amorphous silicon. The new crystalline silicon structure of the Artis Q.zen detector is more homogenous, allowing for more effective amplification of the signal, greatly reducing the electronic noise even at ultra-low doses. Other new 3D applications can image the smallest structures inside the head. Their high spatial resolution is crucial for imaging intracranial stents or other miniscule structures, such as the cochlea in the inner ear. Moving organs such as the lungs can be imaged in 3D in less than 3 seconds, reducing the number of motion artifacts and the amount of contrast agent required.

Source : http://www.siemens.com/press/en/pressrelease/?press=/en/pressrelease/2012/healthcare/imaging-therapy-systems/him201211007.htm

Related Posts Plugin for WordPress, Blogger...

Full story

Page 1 of 712345...Last »
Copyright © 2017 Medical Technology & Gadgets Blog MedicalBuy.net. All rights reserved.
Proudly powered by WordPress. Developed by Deluxe Themes